Bayer Backs Eylea's Prospects Despite Lucentis Biosimilars
Market leader In Wet AMD Still Selling Strongly
Competition, both branded and generic, is on the rise but the German group believes that Eylea will continue to outperform given its safety and efficacy profile and the potential of a longer-lasting version of the eye therapy.
